While IVIG is widely considered a safe and effective treatment, not everyone is a candidate due to cost, logistical ...

This pilot clinical trial evaluated safety and tolerability of intravenous immunoglobulin (IVIG ... using 3T MRI was performed before and after treatment. Results Nine subjects were enrolled ...

Takeda's HYQVIA receives approval in Japan for treating immunodeficiencies, offering a more convenient, less frequent subcutaneous infusion option.

Results from a phase 2 clinical trial showed that treatment with an IgG-cleaving enzyme for individuals diagnosed with Guillain-Barré syndrome led to faster muscle strength recovery and mobility.

Potential treatment options may also preserve wider immune function. Abouzahr says that achieving this would mean endogenous IgG production remains unaffected, and other key immunity guardians ...

With an ever increasing number of patients being treated with IVIg for a wide array of immune-mediated disease, it is important that passive antibody transfer is considered when unexpected ...

5 It has a rapid onset of action, cleaving IgG-antibodies and inhibiting their ... the trade name IDEFIRIX ® for the desensitization treatment of highly sensitized adult kidney transplant ...

which has been approved for many IgG-mediated autoimmune disorders. The second risk to consider would be in terms of Batoclimab being evaluated in the phase 3 study for the treatment of patients ...

This approval introduces the first and only facilitated subcutaneous immunoglobulin (fSCIG) therapy in Japan, offering patients a new treatment option. HYQVIA combines subcutaneous immunoglobulin ...